Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc. (TERN) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · TERN · as of Sep 30, 2025
Ownership Breakdown
150
Institutional Holders
▲ 19 vs Q2
$665.80M
Total Inst. Value
▲ $355.80M vs Q2
90.08M
Shares Outstanding
freeFloat 99.72%
88.65M
13F Shares Held
▲ 5.54M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
TERN largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
SOLEUS CAPITAL MANAGEMENT, L.P. pharmaceutical preparations | 8.13M | 8.87% | 8.87% | $61.03B | Nov 14, 2025 | ▼ 40.0K |
MORGAN STANLEY pharmaceutical preparations | 7.59M | 8.29% | 8.29% | $56.99B | May 27, 2026 | ▲ 335.6K |
ORBIMED ADVISORS LLC pharmaceutical preparations | 7.56M | 8.26% | 8.26% | $56.80B | Nov 14, 2025 | — held |
DEEP TRACK CAPITAL, LP pharmaceutical preparations | 7.50M | 8.18% | 8.18% | $56.29B | Nov 14, 2025 | — held |
VIVO CAPITAL, LLC pharmaceutical preparations | 6.90M | 7.53% | 7.53% | $51.79B | Nov 14, 2025 | — held |
COMMODORE CAPITAL LP pharmaceutical preparations | 5.70M | 6.22% | 6.22% | $42.81B | Nov 14, 2025 | NEW |
BLACKROCK, INC. pharmaceutical preparations | 5.55M | 6.06% | 6.06% | $41.69B | Nov 12, 2025 | ▲ 80.9K |
VANGUARD GROUP INC pharmaceutical preparations | 4.56M | 4.98% | 4.98% | $34.24B | Nov 7, 2025 | ▲ 253.8K |
ADAGE CAPITAL PARTNERS GP, L.L.C. pharmaceutical preparations | 3.94M | 4.30% | 4.30% | $29.58B | Nov 14, 2025 | ▲ 2.66M |
CANDRIAM S.C.A. pharmaceutical preparations | 2.37M | 2.59% | 2.59% | $17.79B | Nov 6, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
26
Increased
+6.54M shares3
New Positions
first time holders15
Decreased
−5.30M shares0
Sold Out
fully exitedNet shares change (top 50)
+1.24M
+6.54M / −5.30M
Net new holders
+14
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
TERN insider trading · insider activity
Source: SEC Form 4
0
Buy transactions
54
Sell transactions
0.00
Buy/Sell ratio
$6M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Azelby Robert director | May 5, 2026 | D-Return | 90,000 | $4.13 | $371.7K | 0 | Form 4 ↗ |
Azelby Robert director | May 5, 2026 | D-Return | 1,697 | $34.60 | $58.7K | 0 | Form 4 ↗ |
Turner Heather D director | May 5, 2026 | D-Return | 45,000 | $4.10 | $184.5K | 0 | Form 4 ↗ |
Turner Heather D director | May 5, 2026 | D-Return | 64,000 | $5.70 | $364.8K | 0 | Form 4 ↗ |
Turner Heather D director | May 5, 2026 | D-Return | 1,697 | $34.60 | $58.7K | 0 | Form 4 ↗ |
Tripuraneni Radhika director | May 5, 2026 | D-Return | 64,000 | $2.13 | $136.3K | 0 | Form 4 ↗ |
Tripuraneni Radhika director | May 5, 2026 | D-Return | 45,000 | $4.10 | $184.5K | 0 | Form 4 ↗ |
Tripuraneni Radhika director | May 5, 2026 | D-Return | 10,657 | $4.46 | $47.5K | 0 | Form 4 ↗ |
Tripuraneni Radhika director | May 5, 2026 | D-Return | 4,676 | $6.85 | $32.0K | 0 | Form 4 ↗ |
Tripuraneni Radhika director | May 5, 2026 | D-Return | 32,000 | $6.99 | $223.7K | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Terns Pharmaceuticals, Inc. (TERN) is primarily owned by institutional investors, who hold approximately 98.4% of total shares outstanding. Company insiders own approximately 0.28%, while retail and public investors account for the remaining 1.31%.
The largest institutional shareholder of Terns Pharmaceuticals, Inc. is SOLEUS CAPITAL MANAGEMENT, L.P., holding approximately 8.13 million shares — equal to 8.87% of outstanding shares — as of September 30, 2025.
A total of 150 institutional investors currently hold TERN stock, with a combined institutional value of approximately $665,796,335 as of the most recent 13F filing period.
Frequently asked questions
TERN ownershipTerns Pharmaceuticals, Inc. (TERN) is primarily owned by institutional investors, who hold approximately 98.4% of shares. The largest shareholder is SOLEUS CAPITAL MANAGEMENT, L.P. with a 8.87% stake. Company insiders hold 0.28%. Data sourced from SEC Form 13F as of September 30, 2025.